Download PDF
Thromb Haemost 2007; 98(06): 1389-1391
DOI: 10.1160/TH07-05-0371
Letters to the Editor
Schattauer GmbH

Fondaparinux as an alternative therapy in heparin-induced delayed-type hypersensitivity skin lesions

Alix c. O’Meara
1   Centre of Oncology/Haematology and Transfusion Medicine, Kantonsspital Aarau, Aarau, Switzerland
,
Franziska Demarmels Biasiutti
2   Division of Haematology and Central Haematology Laboratory, Inselspital, University Hospital, Bern, Switzerland
,
Marc Heizmann
1   Centre of Oncology/Haematology and Transfusion Medicine, Kantonsspital Aarau, Aarau, Switzerland
› Author Affiliations
Further Information

Publication History

Received 27 May 2007

Accepted after resubmission 14 October 2007

Publication Date:
30 November 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Bircher AJ, Harr T, Hohenstein L. et al. Hypersensitivity reactions to anticoagulant drugs: diagnosis and management options. Allergy 2006; 61: 1432-1440.
    CrossrefPubMedGoogle Scholar
  • 2 Pierre RIM, Thiele J, Vardiman JW. et al. Polycythaemia vera. In: WHO Classification: Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001: 32-34.
    PubMedGoogle Scholar
  • 3 Utikal J, Peitsch WK, Booken D. et al. Hypersensitivity to the pentasaccharide fondaparinux in patients with delayed-type heparin allergy. Thromb Haemost 2005; 94: 895-896.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Handschin AE, Trentz O, Kock HJ. et al. Low molecular weight heparin-induced skin necrosis- a systematic review. Langenbecks Arch Surg 2005; 390: 249-254.
    CrossrefPubMedGoogle Scholar
  • 5 Gaigl Z, Pfeuffer P, Raith P. et al. Tolerance to intravenous heparin in patients with delayed-type hypersensitivity to heparins: a prospective study. Br J Haematol 2004; 128: 389-392.
    PubMedGoogle Scholar
  • 6 Patel R, Lim Z, Dawe S. et al. Heparin-induced skin necrosis. Br J Haematol 2005; 129: 712.
    CrossrefPubMedGoogle Scholar
  • 7 Balestra B, Quadri P, Demarmels Biasiutti F. et al. Low molecular weight heparin-induced thrombocytopenia and skin necrosis distant from injection sites. Eur J Haematol 1994; 53: 61-63.
    PubMedGoogle Scholar
  • 8 Warkentin TE, Roberts RS, Hirsh J. et al. Heparininduced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study. Chest 2005; 127: 1857-1861.
    CrossrefPubMedGoogle Scholar
  • 9 Fontana P, Bodmer A, Gruel Y. et al. Skin necrosis is a clinical manifestation of low-molecular weight heparin- induced thrombocytopenia. Thromb Haemost 2004; 91: 196-197.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Jappe U, Juschka U, Kuner N. et al. Fondaparinux: a suitable alternative in cases of delayed-type allergy to heparins and semisynthetic heparinoids? A study of 7 cases. Contact Dermatitis 2004; 51: 67-72.
    CrossrefPubMedGoogle Scholar
  • 11 Maetzke J, Hinrichs R, Schneider LA. et al. Unexpected delayed-type hypersensitivity skin reactions to the ultra-low-molecular-weight heparin fondaparinux. Allergy 2005; 60: 413-415.
    CrossrefPubMedGoogle Scholar
  • 12 Hohenstein E, Tsakiris D, Bircher AJ. Delayed-type hypersensitivity to the ultra-low-molecular-weight heparin fondaparinux. Contact Dermatitis 2004; 51: 149-151.
    CrossrefPubMedGoogle Scholar
  • 13 Hirsch K, Ludwig RJ, Lindhoff-Last E. et al. Intolerance of fondaparinux in a patient allergic to heparins. Contact Dermatitis 2004; 50: 383-384.
    CrossrefPubMedGoogle Scholar
  • 14 Mazzolai L, Hohlfeld P, Spertini F. et al. Fondaparinux is a safe alternative in case of heparin intolerance during pregnancy. Blood 2006; 108: 1569-1570.
    CrossrefPubMedGoogle Scholar
  • 15 Koch P. Delayed-type hypersensitivity skin reactions due to heparins and heparinoids. Tolerance of recombinant hirudins and of the new synthetic anticoagulant fondaparinux. Contact Dermatitis 2004; 49: 276-280.
    PubMedGoogle Scholar
  • 16 Parody R, Oliver A, Souto JC. et al. Fondaparinux (ARIXTRA) as an alternative anti-thrombotic prophylaxis when there is hypersensitivity to low molecular weight and unfractionated heparins. Haematologica 2003; 88: 32.
    PubMedGoogle Scholar
  • 17 Ludwig RJ, Schindewolf M, Utikal J. et al. Management of cutaneous type IV hypersensitivity reactions induced by heparin. Thromb Haemost 2006; 96: 611-617.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Kher A, Bauersachs R, Nielsen JD. The management of thrombosis in pregnancy: role of low-molecular- weight heparin. Thromb Haemost 2007; 97: 505-513.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Sacher C, Hunzelmann N. Tolerance to the synthetic pentasaccharide fondaparinux in heparin sensitization. Allergy 2003; 58: 1318-1319.
    CrossrefPubMedGoogle Scholar
  • 20 Ludwig RJ, Beier C, Lindhoff-Last E. et al. Tolerance of fondaparinux in a patient allergic to heparins and other glycosaminoglycans. Contact Dermatitis 2003; 49: 158-159.
    CrossrefPubMedGoogle Scholar
  • 21 Maetzke J, Hinrichs R, Staib G. et al. Fondaparinux as a novel therapeutic alternative in a patient with heparin allergy. Allergy 2004; 59: 237-238.
    CrossrefPubMedGoogle Scholar
  • 22 Grims RH, Weger W, Reiter H. et al. Delayed-type hypersensitivity to low molecular weight heparins and heparinoids: cross-reactivity does not depend on molecular weight. Br J Dermatol 2007; 157: 514-517.
    CrossrefPubMedGoogle Scholar